Matches in SemOpenAlex for { <https://semopenalex.org/work/W1817360198> ?p ?o ?g. }
- W1817360198 abstract "Background High grade glioma (HGG) is an aggressive form of brain cancer. Treatment of HGG usually entails biopsy, or resection if safe, followed by radiotherapy. Temozolomide is a novel oral chemotherapy drug that penetrates into the brain and purportedly has a low incidence of adverse events. Objectives To assess whether temozolomide has any advantage for treating HGG in either primary or recurrent disease settings. Search methods The following databases were searched: CENTRAL (Issue 10, 2012), MEDLINE, EMBASE, Science Citation Index, Physician Data Query and the Meta‐Register of Controlled Trials in October, 2012. Reference lists of identified studies were searched. The Journal of Neuro‐Oncology and Neuro‐oncology were handsearched from 1999 to 2012 including conference abstracts. We contacted neuro‐oncologists regarding ongoing and unpublished trials. Selection criteria Randomised controlled trials (RCTs) where the interventions were the use of temozolomide during primary therapy or for recurrent disease. Comparisons included no chemotherapy, non‐temozolomide chemotherapy or different dosing schedules of temozolomide. Patients included those of all ages with histologically proven HGG. Data collection and analysis Two review authors undertook the quality assessment and data extraction. Outcome measures included: overall survival (OS); progression‐free survival (PFS); quality of life (QoL); and adverse events. Main results For primary therapy three RCTs were identified, enrolling a total of 745 patients, that investigated temozolomide in combination with radiotherapy versus radiotherapy alone for glioblastoma multiforme (GBM). Temozolomide increased OS (hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.46 to 0.79, P value 0.0003) and increased PFS (HR 0.63, 95% CI 0.43 to 0.92, P value 0.02), when compared with radiotherapy alone, although these benefits only appear to emerge when therapy is given in both concomitant and adjuvant phases of treatment. A single RCT found that temozolomide did not have a statistically significant effect on QoL. Risk of haematological complications, fatigue and infections were increased with temozolomide. In recurrent HGG, two RCTs enrolling 672 patients in total found that temozolomide did not increase OS compared to standard chemotherapy (HR 0.9, 95% CI 0.76 to 1.06, P value 0.2) but it did increase PFS in a subgroup analysis of grade IV GBM tumours (HR 0.68, 95% CI 0.51 to 0.90, P value 0.008). Adverse events were similar between arms. In the elderly, 2 RCTs of 664 patients found OS and PFS was similar with temozolomide alone versus radiotherapy alone. QoL did not appear to differ between arms in a single trial but certain adverse events were significantly more common with temozolomide. Authors' conclusions Temozolomide when given in both concomitant and adjuvant phases is an effective primary therapy in GBM compared to radiotherapy alone. It prolongs survival and delays progression without impacting on QoL but it does increase early adverse events. In recurrent GBM, temozolomide compared with standard chemotherapy improves time‐to‐progression (TTP) and may have benefits on QoL without increasing adverse events but it does not improve overall. In the elderly, temozolomide alone appears comparable to radiotherapy in terms of OS and PFS but with a higher instance of adverse events." @default.
- W1817360198 created "2016-06-24" @default.
- W1817360198 creator A5012494940 @default.
- W1817360198 creator A5024451410 @default.
- W1817360198 creator A5082547447 @default.
- W1817360198 creator A5084915686 @default.
- W1817360198 creator A5088604782 @default.
- W1817360198 date "2013-04-30" @default.
- W1817360198 modified "2023-10-17" @default.
- W1817360198 title "Temozolomide for high grade glioma" @default.
- W1817360198 cites W1565623803 @default.
- W1817360198 cites W1566345389 @default.
- W1817360198 cites W1716422017 @default.
- W1817360198 cites W1817360198 @default.
- W1817360198 cites W1843279041 @default.
- W1817360198 cites W1893588436 @default.
- W1817360198 cites W1921275294 @default.
- W1817360198 cites W1963744937 @default.
- W1817360198 cites W1964906491 @default.
- W1817360198 cites W1968539220 @default.
- W1817360198 cites W1973027090 @default.
- W1817360198 cites W1977392502 @default.
- W1817360198 cites W1979180283 @default.
- W1817360198 cites W1993808515 @default.
- W1817360198 cites W1994769053 @default.
- W1817360198 cites W2002817467 @default.
- W1817360198 cites W2010779703 @default.
- W1817360198 cites W2015660037 @default.
- W1817360198 cites W2033890227 @default.
- W1817360198 cites W2063966329 @default.
- W1817360198 cites W2066343654 @default.
- W1817360198 cites W2075642745 @default.
- W1817360198 cites W2086216067 @default.
- W1817360198 cites W2092939529 @default.
- W1817360198 cites W2096287682 @default.
- W1817360198 cites W2096724244 @default.
- W1817360198 cites W2100848922 @default.
- W1817360198 cites W2103672421 @default.
- W1817360198 cites W2107328434 @default.
- W1817360198 cites W2107731988 @default.
- W1817360198 cites W2112091170 @default.
- W1817360198 cites W2113012900 @default.
- W1817360198 cites W2116583846 @default.
- W1817360198 cites W2133611748 @default.
- W1817360198 cites W2136176313 @default.
- W1817360198 cites W2137013555 @default.
- W1817360198 cites W2140746183 @default.
- W1817360198 cites W2140859993 @default.
- W1817360198 cites W2144161044 @default.
- W1817360198 cites W2148896175 @default.
- W1817360198 cites W2149477053 @default.
- W1817360198 cites W2154526619 @default.
- W1817360198 cites W2158681922 @default.
- W1817360198 cites W2160382843 @default.
- W1817360198 cites W2162494092 @default.
- W1817360198 cites W2162643152 @default.
- W1817360198 cites W2165871546 @default.
- W1817360198 cites W2170129724 @default.
- W1817360198 cites W2264385870 @default.
- W1817360198 cites W2410936318 @default.
- W1817360198 cites W2418968497 @default.
- W1817360198 cites W2471032030 @default.
- W1817360198 cites W2536552580 @default.
- W1817360198 cites W3046931500 @default.
- W1817360198 cites W4235695024 @default.
- W1817360198 cites W4243604983 @default.
- W1817360198 cites W4244632132 @default.
- W1817360198 doi "https://doi.org/10.1002/14651858.cd007415.pub2" @default.
- W1817360198 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6457743" @default.
- W1817360198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23633341" @default.
- W1817360198 hasPublicationYear "2013" @default.
- W1817360198 type Work @default.
- W1817360198 sameAs 1817360198 @default.
- W1817360198 citedByCount "104" @default.
- W1817360198 countsByYear W18173601982013 @default.
- W1817360198 countsByYear W18173601982014 @default.
- W1817360198 countsByYear W18173601982015 @default.
- W1817360198 countsByYear W18173601982016 @default.
- W1817360198 countsByYear W18173601982017 @default.
- W1817360198 countsByYear W18173601982018 @default.
- W1817360198 countsByYear W18173601982019 @default.
- W1817360198 countsByYear W18173601982020 @default.
- W1817360198 countsByYear W18173601982021 @default.
- W1817360198 countsByYear W18173601982022 @default.
- W1817360198 countsByYear W18173601982023 @default.
- W1817360198 crossrefType "journal-article" @default.
- W1817360198 hasAuthorship W1817360198A5012494940 @default.
- W1817360198 hasAuthorship W1817360198A5024451410 @default.
- W1817360198 hasAuthorship W1817360198A5082547447 @default.
- W1817360198 hasAuthorship W1817360198A5084915686 @default.
- W1817360198 hasAuthorship W1817360198A5088604782 @default.
- W1817360198 hasBestOaLocation W18173601981 @default.
- W1817360198 hasConcept C126322002 @default.
- W1817360198 hasConcept C143998085 @default.
- W1817360198 hasConcept C197934379 @default.
- W1817360198 hasConcept C207103383 @default.
- W1817360198 hasConcept C2776694085 @default.
- W1817360198 hasConcept C2777389519 @default.
- W1817360198 hasConcept C2778227246 @default.
- W1817360198 hasConcept C44249647 @default.